Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

Clinical- and biomarker-based tools may identify a lower-risk acute graft-versus-host disease (GVHD) population amenable to novel, reduced-intensity treatments. Previous data suggest sirolimus may rival standard of care prednisone. We conducted a National Heart, Lung, and Blood Institute/National Ca...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2020-01, Vol.135 (2), p.97-107
Hauptverfasser:	Pidala, Joseph, Hamadani, Mehdi, Dawson, Peter, Martens, Michael, Alousi, Amin M., Jagasia, Madan, Efebera, Yvonne A., Chhabra, Saurabh, Pusic, Iskra, Holtan, Shernan G., Ferrara, James L.M., Levine, John E., Mielcarek, Marco, Anasetti, Claudio, Antin, Joseph H., Bolaños-Meade, Javier, Howard, Alan, Logan, Brent R., Leifer, Eric S., Pritchard, Theresa S., Horowitz, Mary M., MacMillan, Margaret L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Adolescent Adult Aged Antibiotics, Antineoplastic - therapeutic use Antineoplastic Agents, Hormonal Bone Marrow Transplantation - adverse effects Child Child, Preschool Clinical Trials and Observations Female Follow-Up Studies Graft vs Host Disease - drug therapy Graft vs Host Disease - pathology Humans Infant Male Middle Aged Prednisone - therapeutic use Prognosis Sirolimus - therapeutic use Survival Rate Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!